[1]CLOUGHESY TF，PETRECCA K，WALBERT T，et al.Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma:A randomized clinical trial［J］.JAMA Oncol,2020,6(12):1939-1946.
[2]LIU S，ZHAO Q，SHI W，et al.Advances in radiotherapy and comprehensive treatment of high-grade glioma:immunotherapy and tumor-treating fields［J］.J Cancer,2021,12(4):1094-1104.
[3]ANTHONY C，MLADKOVA-SUCHY N，ADAMSON DC.The evolving role of antiangiogenic therapies in glioblastoma multiforme:current clinical significance and future potential［J］.Expert Opin Investig Drugs,2019,28(9):787-797.
[4]HUANG R，BOLTZE J，LI S.Strategies for improved intra-arterial treatments targeting brain tumors:a systematic review［J］.Front Oncol,2020,10:1443.
[5]D'AMICO RS，KHATRI D，REICHMAN N，et al.Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption:where are we now，and where we are going［J］.J Neurooncol,2020,147(2):261-278.
[6]AQUINO D，GIOPPO A，FINOCCHIARO G，et al.MRI in glioma immunotherapy:Evidence，pitfalls，and perspectives［J］.J Immunol Res,2017,2017:5813951.
[7]BENDER K，TRAGER M，WAHNER H，et al.What is the role of the subventricular zone in radiotherapy of glioblastoma patients［J］.Radiother Oncol,2021,158:138-145.
[8]LUKAS RV，WAINWRIGHT DA，LADOMERSKY E，et al.Newly diagnosed glioblastoma:A review on clinical management［J］.Oncology（Williston Park),2019,33(3):91-100.
[9]GARCIA J，HURWITZ HI，SANDLER AB，et al.Bevacizumab［Avastin(R)］ in cancer treatment:A review of 15 years of clinical experience and future outlook［J］.Cancer Treat Rev,2020,86:102017.
[10]颜成睿，张梦雨，马文斌.应用贝伐珠单抗治疗高级别胶质瘤的研究进展［J］.中华神经外科杂志,2016,32(1):88-90.
YAN CR，ZHANG MY，MA WB，et al.Research progress in bevacizumab treatment of high grade glioma［J］.Chinese Journal of Neurosurgery,2016,32(1):88-90.
[11]国家卫生健康委员会医政医管局.脑胶质瘤诊疗规范(2018年版)［J］.中华神经外科杂志,2019,35(3):217-239.
Medical Administration and Management Bureau of National Health Commission.Diagnosis and treatment specifications for glioma（2018 Edition)［J］.Chinese Journal of Neurosurgery,2019,35(3):217-239.
[12]SEPULVEDA JM，BELDA-INIESTA C，GIL-GIL M，et al.A phase Ⅱ study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma［J］.Clin Transl Oncol,2015,17(9):743-750.
[13]徐娟，王冬青，于水，等.贝伐珠单抗治疗复发高级别脑胶质瘤的临床观察［J］.临床肿瘤学杂志,2020,25(7):640-643.
XU J,WANG DQ,YU S，et al.Clinical observation of bevacizumab in the treatment of recurrent high-grade glioma［J］.Chinese Clinical Oncology，2020,25(7):640-643.
[14]杨群英，郭琤琤，林富华，等.贝伐珠单抗治疗复发恶性脑胶质瘤36例临床分析［J］.广东医学,2017,38(1):38-41.
YANG QY，GUO ZZ，LIN FH，et al.Bevacizumab in the treatment of recurrent malignant gliomas:a report of 36 cases［J］.Guangdong Medical Journal，2017,38(1):38-41.
[15]李化龙，强铭，黄小琴，等.贝伐珠单抗联合替莫唑胺治疗恶性复发脑胶质瘤的疗效［J］.安徽医学,2020,41(1):66-68.
LI HL，QIANG M，HUANG XQ，et al.Efficacy of bevacizumab combined with temozolomide in the treatment of malignant recurrent glioma［J］.Anhui Medical Journal，2020,41(1):66-68.
[16]BADRUDDOJA MA，PAZZI M，SANAN A，et al.Phase Ⅱ study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma［J］.Cancer Chemother Pharmacol,2017,80(4):715-721.
[17]FALTINGS L，KULASON KO，PATEL NV，et al.Rechallenging recurrent glioblastoma with intra-arterial bevacizumab with blood brain-barrier disruption results in radiographic response［J］.World Neurosurg,2019,131:234-241.
[18]HASHIMOTO Y，CAMPBELL M.Tight junction modulation at the blood-brain barrier:Current and future perspectives［J］.Biochim Biophys Acta Biomembr,2020,1862(9):183298.
[19]MARCUCCI F，CORTI A，FERRERI A.Breaching the blood-brain tumor barrier for tumor therapy［J］.Cancers（Basel),2021,13:2391-2409.